EKF Diagnostics Holdings PLC logo

EKF Diagnostics Holdings PLC (EKF)

Market Closed
13 Feb, 00:00
LSE LSE
£
25. 80
+1.8
+7.5%
£
133.85M Market Cap
- P/E Ratio
4.8% Div Yield
176,344 Volume
- Eps
£ 24
Previous Close
Add Transaction
Day Range
24.2 25.8
Year Range
18.4 32
Want to track EKF and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

EKF closed Friday higher at £25.8, an increase of 7.5% from Thursday's close, completing a monthly increase of 0% or £25.8. Over the past 12 months, EKF stock gained 0%.
EKF pays dividends to its shareholders, with the most recent payment made on Dec 01, 2023. The next estimated payment will be in 1 Dec 2023 on Dec 01, 2023 for a total of £0.012.
The last earnings report, released on Sep 24, 2024, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 2 different exchanges and in various currencies, with the primary listing on LSE (GBP).

EKF Chart

People also search for

Digia Oyj
5.95
-1.8152%
Scancell Holdings PLC
£ 13.25
0%
Faron Pharmaceuticals Oy
£ 162.5
-1.5152%
Nanobiotix S.A.
32.78
-1.0266%
Creo Medical Group plc
£ 16.75
0%

EKF Diagnostics Holdings PLC (EKF) FAQ

What is the stock price today?

The current price is £25.80.

On which exchange is it traded?

EKF Diagnostics Holdings PLC is listed on LSE.

What is its stock symbol?

The ticker symbol is EKF.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 4.8%.

What is its market cap?

As of today, the market cap is 133.85M.

Has EKF Diagnostics Holdings PLC ever had a stock split?

No, there has never been a stock split.

EKF Diagnostics Holdings PLC Profile

Health Care Equipment & Supplies Industry
Healthcare Sector
Gavin Joseph Jones CEO
LSE Exchange
G30891108 CUSIP
GB Country
303 Employees
- Last Dividend
- Last Split
- IPO Date

Overview

EKF Diagnostics Holdings plc is a global medical diagnostics company engaged in designing, developing, manufacturing, and selling a wide range of diagnostic instruments, reagents, and ancillary products. The company has a broad market reach, serving customers in Europe, the Middle East, the Americas, Asia, and Africa. Founded in 1990 and headquartered in Cardiff, United Kingdom, EKF Diagnostics stands out for its innovative solutions in the medical field, focusing on providing high-quality, reliable diagnostic tools and services to healthcare professionals and patients around the world.

Products and Services

  • DiaSpect Tm and DiaSpect Hemoglobin T: Portable hand-held analyzers used for quick and reliable hemoglobin measurements.
  • Hemo Control: Offers lab-quality hemoglobin results, catering to the need for accurate blood analysis.
  • HemataStat II: A microhematocrit centrifuge providing quantitative hematocrit readings for six blood samples, facilitating efficient sample processing.
  • Biosen C-Line GP+ and C-Line Clinic: Glucose and lactate analyzers designed for clinical and sports medicine applications, ensuring accurate and fast results.
  • Quo-Lab A1c and Quo-Test A1c: Compact, desktop analyzers focused on measuring glycated hemoglobin for diabetes monitoring and management.
  • STAT-Site M Beta-hydroxybutyrate: Analyzer for beta-hydroxybutyrate, aiding in the monitoring of ketosis in patients.
  • Creamatocrit Plus: Analyzes lipid concentration and calorific density in mothers' milk, supporting neonatal health.
  • QuPID and True20 Pregnancy Tests: Reliable, quick pregnancy tests for professional and home use.
  • Lactate Scout 4: A lactate analyzer, perfect for sports and medical use, providing critical data for performance and patient care.
  • Clinical Chemical Analyzers and Assays: A range of products including analyzers and markers for glycated albumin, glycated serum protein, nitro-tab ketone, and procalcitonin for diverse clinical applications from ketosis monitoring to bacterial infection and sepsis detection.
  • RaPET Serology Immunoassay Kits: For immunoassay applications, ensuring reliable serological testing.
  • QuStick Strep A: Facilitates the rapid detection and treatment of Strep A infection, improving patient outcomes.
  • Altair 240, Excel, Micro 12: A lineup of clinical analyzers and centrifuges catering to various diagnostic needs, from blood chemistry analysis to molecular and bacteriological applications.
  • Hema-Screen Serology: Analyzers for early detection of colorectal cancer, highlighting the company’s commitment to cancer diagnostics.
  • Uri-Trak 120: A urine analyzer designed for accurate and efficient urinalysis, supporting comprehensive urinary tract health assessment.
  • COVID-19 Kits and Services: Includes a variety of diagnostic kits and services related to COVID-19, responding to the global health emergency with timely and effective solutions.
  • Contract Manufacturing and Laboratory Services: Offers contract manufacturing solutions to third-party businesses and extensive laboratory services, showcasing EKF Diagnostics’ versatility and comprehensive service offerings in the medical diagnostics field.

Contact Information

Address: Avon House
Phone: 44 29 2071 0570